SHANGHAI, July 5, 2024 /PRNewswire/ -- Chime Biologics, a
leading global CDMO that enables its partners' success in
biologics, affirmed its commitment to innovation and quality at the
recent China Biologics Going Global Forum held in Shanghai.
Dr. Jimmy Wei, President of Chime
Biologics, highlighted that the company's competitive edge arises
from ensuring product quality, leveraging efficiencies, and
maintaining stringent cost controls. Chime Biologics' lead
investor, VMS Group, also attended this forum. Andrew Ng, Partner and Head of Healthcare of VMS
Group, shared that since 2017, about 70% of VMS healthcare
investments have been in the Greater
China region, with the remainder invested in the global
market, especially in Europe and
the United States.
Bing Chen, Vice President of International BD and Venture Fund
at AstraZeneca mentioned that it was previously sufficient for
innovative medicines to be a regional leader, but winning products
now need to be best-in-class globally. By launching best-in-class
products, Chinese pharmaceutical companies are more likely to
attract additional global collaboration opportunities.
Speeding Up Globalization
In a roundtable discussion moderated by Dr. Hongtao Lu, co-founder and Chief Scientist of
Elpiscience, a panel of industry leaders noted that though local
pharmaceuticals have created many clinically valuable products such
as bispecific antibodies that are typically used for cancer
treatment, there are relatively few products that leaped from zero
to one.
Global CDMOs such as Chime Biologics play an important role in
global innovation, with a significant increase in licensing deals
between local biotech companies and U.S./European biopharmaceutical
companies, especially in license-out deals. Chime Biologics can
help biotech companies go to market from the pre-clinical to
commercial manufacturing stages, leading to a win-win situation,
which will be a major trend in the next decade.
Charting a Sustainable Growth Trajectory
Dr. Jimmy Wei, President of Chime
Biologics, observed that: "Foreign biopharmaceutical companies have
gone through several market cycles, and when they choose CDMOs,
they are more concerned about its long-term developmental
prospects, the technology level, and whether the quality systems
are aligned with international standards. Domestic companies also
have higher requirements when looking for partners now."
With a focus on innovation and quality, the Chinese
biopharmaceutical industry is actively charting a sustainable
growth trajectory internationally, which was often echoed by
speakers and panelists at this forum when discussing drivers to
enhance the industry's global presence and competitiveness in
international markets.
View original
content:https://www.prnewswire.co.uk/news-releases/going-global---chime-biologics-embraces-innovation-and-quality-with-partners-302189836.html